A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : EAT / Ehrlich ascites tumor

[Related PubMed/MEDLINE]
Total Number of Papers: 339
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   EAT  (>> Co-occurring Abbreviation)
Long Form:   Ehrlich ascites tumor
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 A new pyrrole based small molecule from Tinospora cordifolia induces apoptosis in MDA-MB-231 breast cancer cells via ROS mediated mitochondrial damage and restoration of p53 activity. TNBC
2019 Acylated chitosan anchored paclitaxel loaded liposomes: Pharmacokinetic and biodistribution study in Ehrlich ascites tumor bearing mice. ---
2018 LQFM030 reduced Ehrlich ascites tumor cell proliferation and VEGF levels. VEGF
2018 Recombinant Inga Laurina Trypsin Inhibitor (ILTI) Production in Komagataella Phaffii Confirms Its Potential Anti-Biofilm Effect and Reveals an Anti-Tumoral Activity. BAPNA, ILTI, rILTI
2017 Folic acid and trastuzumab conjugated redox responsive random multiblock copolymeric nanocarriers for breast cancer therapy: In-vitro and in-vivo studies. FACS
2017 Suppression of VEGF-induced angiogenesis and tumor growth by Eugenia jambolana, Musa paradisiaca, and Coccinia indica extracts. CAM, EA, EC, NB
2017 Synthesis, characterization and augmented anticancer potential of PEG-betulinic acid conjugate. BA, mPEG
2016 Enhanced anti-tumor efficacy of paclitaxel with PEGylated lipidic nanocapsules in presence of curcumin and poloxamer: In vitro and in vivo studies. D-LNCs, i.v
2016 Induction of apoptosis in Ehrlich ascites tumour cells via p53 activation by a novel small-molecule MDM2 inhibitor - LQFM030. ---
10  2016 Oxidative stress, polarization of macrophages and tumour angiogenesis: Efficacy of caffeic acid. CA, TAMs
11  2016 Polarization of macrophages towards M1 phenotype by a combination of 2-deoxy-d-glucose and radiation: Implications for tumor therapy. 2-DG
12  2016 Regulation of apoptosis through bcl-2/bax proteins expression and DNA damage by Zanthoxylum alatum. MEZA
13  2016 The augmented anticancer potential of AP9-cd loaded solid lipid nanoparticles in human leukemia Molt-4 cells and experimental tumor. SLNs
14  2016 The effects of silibin administration for different time periods on mouse liver with Ehrlich ascites carcinoma. i.p, PCNA, sb, TUNEL
15  2015 Modulation of Cytokines Production by Indomethacin Acute Dose during the Evolution of Ehrlich Ascites Tumor in Mice. ---
16  2015 Novel synthetic bisbenzimidazole that targets angiogenesis in Ehrlich ascites carcinoma bearing mice. FDPB, VEGF
17  2015 pH-Sensitive Biocompatible Nanoparticles of Paclitaxel-Conjugated Poly(styrene-co-maleic acid) for Anticancer Drug Delivery in Solid Tumors of Syngeneic Mice. EPR, NPs, PSMAC-PTX, PTX
18  2015 Preclinical Evaluation of a Potential GSH Ester Based PET/SPECT Imaging Probe DT(GSHMe)₂ to Detect Gamma Glutamyl Transferase Over Expressing Tumors. CT, GGT, GSHMe, GSHMe, PET
19  2015 ROP and ATRP Fabricated Dual Targeted Redox Sensitive Polymersomes Based on pPEGMA-PCL-ss-PCL-pPEGMA Triblock Copolymers for Breast Cancer Therapeutics. ATRP, ROP
20  2015 Synergic carcinostatic effects of ascorbic acid and hyperthermia on Ehrlich ascites tumor cell. AsA, CRet
21  2014 Addition of propolis to irinotecan therapy prolongs survival in ehrlich ascites tumor-bearing mice. IRI
22  2014 Anti-proliferative and angio-suppressive effect of Stoechospermum marginatum (C. Agardh) Kutzing extract using various experimental models. SME
23  2014 Characterization of Lin⁻ALDH (bright) population using Ehrlich ascites tumor cells in mice. ALDH, CSCs, MDR, Rh123
24  2014 Enhanced antitumor immunity contributes to the radio-sensitization of ehrlich ascites tumor by the glycolytic inhibitor 2-deoxy-D-glucose in mice. ---
25  2014 Glucose uptake-stimulatory activity of Tinospora cordifolia stem extracts in Ehrlich ascites tumor cell model system. GLUT1, T. cordifolia
26  2014 Intracellular delivery of peptide cargos using iron oxide based nanoparticles: studies on antitumor efficacy of a BCL-2 converting peptide, NuBCP-9. ---
27  2014 Surface engineered nanostructured lipid carriers for targeting MDR tumor: Part II. In vivo biodistribution, pharmacodynamic and hematological toxicity studies. NLC-Ir
28  2013 A pro-apoptotic 15-kDa protein from Bacopa monnieri activates caspase-3 and downregulates Bcl-2 gene expression in mouse mammary carcinoma cells. BMWE, CAD
29  2013 Antitumour and anti-inflammatory effects of palladium(II) complexes on Ehrlich tumour. IL-10, IL-12, NO, PECs, TNF-alpha
30  2013 Augmented anticancer activity of a targeted, intracellularly activatable, theranostic nanomedicine based on fluorescent and radiolabeled, methotrexate-folic Acid-multiwalled carbon nanotube conjugate. FR, MWCNTs
31  2013 Design, synthesis, and anticancer properties of novel benzophenone-conjugated coumarin analogs. MCF-7, PI3K
32  2013 Effect of flavonoids and hyperthermal intraperitoneal chemotherapy on tumour growth and micronucleus induction in mouse tumour model. CP, NAR, QU
33  2013 Gracilaria edulis extract induces apoptosis and inhibits tumor in Ehrlich ascites tumor cells in vivo. EEGE, ROS
34  2013 Melatonin effect on the ultrastructure of Ehrlich ascites tumor cells, lifetime and histopathology in Swiss mice. ---
35  2013 NF-kappaB down-regulation and PARP cleavage by novel 3-alpha-butyryloxy-beta-boswellic acid results in cancer cell specific apoptosis and in vivo tumor regression. BOBA, EAC
36  2013 Sleep deprivation increases mortality in female mice bearing Ehrlich ascitic tumor. ---
37  2013 Synergism between propolis and hyperthermal intraperitoneal chemotherapy with cisplatin on ehrlich ascites tumor in mice. HIPEC, WSDP
38  2012 2,4,8-trihydroxybicyclo [3.2.1]octan-3-one scavenges free radicals and protects against xenobiotic-induced cytotoxicity. LPO, NO, ROS
39  2012 4-(2-Hydroxypropan-2-yl)-1-methylcyclohexane-1,2-diol prevents xenobiotic induced cytotoxicity. HPMCD, LPO, ROS
40  2012 Ameliorative influence of Urtica dioica L against cisplatin-induced toxicity in mice bearing Ehrlich ascites carcinoma. CP, UDME
41  2012 Anticancer effects of synthetic phosphoethanolamine on Ehrlich ascites tumor: an experimental study. ALPs, Pho-s, PI
42  2012 Autophagy inhibited Ehrlich ascitic tumor cells apoptosis induced by the nitrostyrene derivative compounds: relationship with cytosolic calcium mobilization. ---
43  2012 beta-1,3-Glucan given orally modulates immunomyelopoietic activity and enhances the resistance of tumour-bearing mice. IFN, IL
44  2012 Hyaluronate tethered, "smart" multiwalled carbon nanotubes for tumor-targeted delivery of doxorubicin. AF-647, DOX, HR, MWCNT-HA
45  2012 Investigation of Ehrlich ascites tumor cell death mechanisms induced by Synadenium umbellatum Pax. CFU-GM, ROS
46  2012 Paclitaxel loaded PEGylated gleceryl monooleate based nanoparticulate carriers in chemotherapy. GMO, PTX
47  2012 The in vivo behavior and antitumor activity of doxorubicin-loaded poly(gamma-benzyl l-glutamate)-block-hyaluronan polymersomes in Ehrlich ascites tumor-bearing BalB/c mice. DOX
48  2011 Antioxidant and cytoprotective properties of 2-(hydroxymethyl)-3-methoxybenzaldehyde. LPO, NO, ROS
49  2011 MicroRNA expression profiles associated with development of drug resistance in Ehrlich ascites tumor cells. MDR, miRNAs
50  2011 Stimulation of glucose uptake by Musa sp. (cv. elakki bale) flower and pseudostem extracts in Ehrlich ascites tumor cells. ---
51  2011 The bradykinin B1 receptor antagonist R-954 inhibits Ehrlich tumor growth in rodents. ---
52  2010 Chlorella vulgaris modulates immunomyelopoietic activity and enhances the resistance of tumor-bearing mice. CSA, CV, LTBMC, SMC
53  2010 Development and characterization of hyaluronic acid decorated PLGA nanoparticles for delivery of 5-fluorouracil. 5-FU
54  2010 Granulocytes as effective anticancer agent in experimental solid tumor models. ---
55  2010 Growth inhibition and pro-apoptotic activity of violacein in Ehrlich ascites tumor. i.p, ROS
56  2010 In vitro and in vivo evaluation of docetaxel loaded biodegradable polymersomes. DOC, DS
57  2010 Inhibition of ascites tumor growth in vivo by sTie-2 is potentiated by a combinatorial therapy with sFLT-1. ---
58  2010 Platelet-activating factor receptor (PAF-R)-dependent pathways control tumour growth and tumour response to chemotherapy. COX-2, NO, PAFR, PGE2, VEGF
59  2010 Protective effects of propolis and related polyphenolic/flavonoid compounds against toxicity induced by irinotecan. MN
60  2010 Sonodynamic effects of protoporphyrin IX disodium salt on Ehrlich ascetic tumor cells. CLSM, PPIX, SEM
61  2010 Stereospecificity in the cytotoxic action of hexachlorocyclohexane isomers. HCH, LDH, LPO, ROS
62  2009 99mTc-DTPA-amino acids conjugate as specific SPECT pharmaceuticals for tumor imaging. ---
63  2009 Antiangiogenic and proapoptotic activities of allyl isothiocyanate inhibit ascites tumor growth in vivo. AITC
64  2009 Antineoplastic and cytogenetic effects of chlorpromazine on human lymphocytes in vitro and on Ehrlich ascites tumor cells in vivo. ---
65  2009 Chemotherapeutic potential of two gallic acid derivative compounds from leaves of Casearia sylvestris Sw (Flacourtiaceae). IGDE, MGDE
66  2009 Cytotoxicity and antiangiogenic activity of grandisin. VEGF
67  2009 Efficient tumor targeting by polysaccharide decked polyethylenimine based nanocomposites. HA, pEGFP
68  2009 Gene expression, biodistribution, and pharmacoscintigraphic evaluation of chondroitin sulfate-PEI nanoconstructs mediated tumor gene therapy. CP, CS
69  2009 Genotoxicity and cytotoxicity of cisplatin treatment combined with anaesthetics on EAT cells in vivo. ---
70  2009 Membrane damage effect of therapeutic ultrasound on Ehrlich ascitic tumor cells. ---
71  2009 Paracrine action of sFLT-1 secreted by stably-transfected Ehrlich ascites tumor cells and therapy using sFLT-1 inhibits ascites tumor growth in vivo. VEGF
72  2009 Synthesis and biological evaluation of (99m)Tc-DTPA-bis(His) as a potential probe for tumor imaging with SPECT. ---
73  2009 The antitumor activities of the structurally-similar two-species aromatics Tonalide and Pearlide and the enhancement of their effects by hyperthermia. ---
74  2008 Antimicrobial and antineoplasic activity of Pleurotus ostreatus. ECB
75  2008 Antineoplasic activity of Copaifera multijuga oil and fractions against ascitic and solid Ehrlich tumor. ---
76  2008 Antitumoral and antiangiogenic activity of Synadenium umbellatum Pax. EESU, SU
77  2008 Evaluation of the antineoplastic activity of L-rhamnose in vitro. A comparison with 2-deoxyglucose. 2-DG
78  2008 Inhibition of in vivo angiogenesis by Anacardium occidentale L. involves repression of the cytokine VEGF gene expression. AOE, VEGF
79  2008 INN-toxin, a highly lethal peptide from the venom of Indian cobra (Naja naja) venom-Isolation, characterization and pharmacological actions. NBS
80  2008 Preparation and characterization of HA-PEG-PCL intelligent core-corona nanoparticles for delivery of doxorubicin. DOX, HA-PEG-PCL, MPEG
81  2008 Preparation and pharmacological evaluation of a new radiopharmaceutical, technetium-99m-5-fluorouracil, for tumor scintigraphy. 5-FU
82  2008 Promotive effects of hyperthermia on the cytostatic activity to Ehrlich ascites tumor cells by diverse delta-alkyllactones. DALs
83  2008 Synthesis and evaluation of 1-benzhydryl-sulfonyl-piperazine derivatives as inhibitors of tumor growth and tumor angiogenesis of mouse ehrlich ascites tumor in vivo. CAM, MST
84  2007 Accumulation of liposome with Sialyl Lewis X to inflammation and tumor region: application to in vivo bio-imaging. DDS, SLX
85  2007 Anti-tumor and anti-invasive effects of diverse delta-alkyllactones: dependence on molecular side-chain length, action period and intracellular uptake. DALs
86  2007 Effect of reduced levels of the LDL receptor of Ehrlich ascites tumor cells on cholesterol uptake and cell proliferation: a coculture study with baby hamster kidney cells. HMG-CoA
87  2007 Effects of ethyl-esterization, chain-lengths, unsaturation degrees, and hyperthermia on carcinostatic effect of omega-hydroxylated fatty acids. omega HFAs, SEM
88  2007 Enhanced antitumor activity of irinotecan combined with propolis and its polyphenolic compounds on Ehrlich ascites tumor in mice. EEP, i.p, WSDP
89  2007 Evaluation of the effect of paclitaxel, epirubicin and tamoxifen by cell kinetics parameters in estrogen-receptor-positive ehrlich ascites tumor (eat) cells growing in vitro. EPI, PAC, TAM
90  2007 In vivo antitumoral activity of stem pineapple (Ananas comosus) bromelain. LLC
91  2007 In vivo antitumoral effect of Plantago major L. extract on Balb/C mouse with Ehrlich ascites tumor. ---
92  2007 In vivo growth inhibitory and anti-angiogenic effects of synthetic novel dienone cyclopropoxy curcumin analogs on mouse Ehrlich ascites tumor. MVD
93  2007 Induction of caspase-3 activated DNase mediated apoptosis by hexane fraction of Tinospora cordifolia in EAT cells. CAD
94  2007 Nephroprotective effect of cystathionine is due to its diverse action on the kidney and Ehrlich ascites tumor cells. CP, CST, CT, GST, NPSH, ROS
95  2007 Pro-apoptotic activity of imidazole derivatives mediated by up-regulation of Bax and activation of CAD in Ehrlich Ascites Tumor cells. ---
96  2007 Purification and characterization of butyrate-induced protein phosphatase involved in apoptosis of Ehrlich ascites tumor cells. BuA
97  2006 Anti-tumor and proapoptotic effect of novel synthetic benzophenone analogues in Ehrlich ascites tumor cells. ---
98  2006 Antitumour activity of [1,2-di(cyclopentadienyl)-1,2-di(p-N,N-dimethylaminophenyl)-ethanediyl] titanium dichloride in xenografted Ehrlich's ascites tumour. CFU-GM, NK
99  2006 Bothrops moojeni myotoxin-II, a Lys49-phospholipase A2 homologue: an example of function versatility of snake venom proteins. BPB, CNBr, NBSF
100  2006 Causal relationship between hexachlorocyclohexane cytotoxicity, oxidative stress and Na+, K +-ATPase in Ehrlich Ascites tumor cells. CAT, HCH, LDH, LPO, ROS, SOD